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IMMUNOBIOLOGY
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Development of hematopoietic cells de-
pends on a dynamic actin cytoskeleton.
Here we demonstrate that expression of the
cytoskeletal regulator WASP, mutated in the
Wiskott-Aldrich syndrome, provides selec-
tive advantage for the development of natu-
rally occurring regulatory T cells, natural
killer T cells, CD4 and CD8 T lympho-
cytes, marginal zone (MZ) B cells, MZ macro-
phages, and platelets. To define the relative
contribution of MZ B cells and MZ macro-
phages for MZ development, we generated
wild-type and WASP-deficient bone marrow
chimeric mice, with full restoration of the
MZ. However, even in the presence of MZ
macrophages, only 10% of MZ B cells were
of WASP-deficient origin. We show that
WASP-deficient MZ B cells hyperproliferate
in vivo and fail to respond to sphingosine-1-
phosphate, a crucial chemoattractant for MZ
B-cell positioning. Abnormalities of the MZ
compartment in WASP/ mice lead to aber-
rant uptake of Staphylococcus aureus and
to a reduced immune response to TNP-
Ficoll. Moreover, WASP-deficient mice have
increased levels of “natural” IgM antibodies.
Our findings reveal that WASP regulates
both development and function of hemato-
poietic cells. We demonstrate that WASP
deficiency leads to an aberrant MZ that may
affect responses to blood-borne pathogens
and peripheral B-cell tolerance. (Blood. 2008;
112:4139-4147)
Introduction
The Wiskott-Aldrich syndrome (WAS) is a severe immunodefi-
ciency characterized by a complex phenotype and an increased
mortality resulting from hemorrhage, severe infections, and malig-
nancy. Defective expression of WAS protein (WASP) leads to
multiple abnormalities in different hematopoietic cells in patients
with WAS and WASP-deficient mice.1 Hematopoietic stem cell
transplantation (HSCT) represents an effective treatment strategy
for severe WAS patients2,3; however, the degree of donor engraft-
ment in various hematopoietic compartments is an important
determination of successful treatment.4 In severe cases, where
suitable donors are unavailable, gene therapy is being considered as
an alternative treatment for WAS.5,6 However, the role of WASP in
the development of hematopoietic cells remains largely unknown.
A detailed analysis of the possible advantage for WASP-expressing
cells over WASP-negative cells in a competitive setting should
provide insight into which lineages are more probable to be
corrected by gene therapy.
The splenic marginal zone (MZ) contains specialized B cells
and highly phagocytic MZ macrophages (MZMs) that create a first
line of defense to blood-borne pathogens.7 Reduced number of MZ
B cells of WAS patients and WASP-deficient mice may contribute
to the weak immune response to bacteria.8,9 The natural MZ B-cell
repertoire has a low self-reactivity that enables them to rapidly
respond to blood-borne antigens.10 MZ B-cell development from
transitional-2-marginal zone precursor (T2-MZP) cells has been
suggested to depend on Notch2-activated gene transcription and on
B-cell receptor (BCR) signaling strength.11,12 Furthermore, MZ
B-cell positioning is critically dependent on interactions with
ICAM-1 and VCAM-1 and responsiveness to sphingosine-1-
phosphate (S1P).13,14 MZ B-cell retention may involve signals from
MZMs because depletion of MZMs leads to a severe reduction of
MZ B cells.15 Accordingly, MZ B-cell development, positioning,
and function depend on both B-cell intrinsic activity and on the
presence of MZMs.
By analyzing WASP-expressing cells in the competitive setting
of WASP/ mice, we show that WASP is essential for development
of nTregs, NKT cells, and to a lesser extent for platelets but is
dispensable for development of myeloid cells. In addition, we show
that WASP directly regulates development, positioning, and func-
tion of MZ B cells and MZMs.
Methods
Mouse strains, mixed bone marrow chimeras, and bone
marrow cultures
Wild-type (WT) Balb/c and C57BL/6 mice were purchased from Charles
River Laboratories (Wilmington, MA). WASP/ and WASP/ mice16 on
Balb/c background (backcrossed 8 generations) were used for all experi-
ments except for those that required an alternative background as follows.
For bone marrow (BM) chimeras, WT C57BL/6 mice expressing CD45.1
were purchased from The Jackson Laboratory (Bar Harbor, ME) and used
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together with WASP/ C57BL/6 mice backcrossed 4 generations (express-
ing CD45.2). WASP/ C57BL/6 mice were used for immunizations
because TNP-Ficoll induces an efficient immune response in WT C57BL/6
mice. WASP//btkxid double-deficient mice were generated by breeding
WASP/ 129Sv mice with btkxid mice (The Jackson Laboratory). For
generation of mixed BM chimeras, 107 total BM cells containing WT and
WASP/ were transplanted via intravenous injection into lethally irradi-
ated (10.5 Gy) WASP/ recipient animals. BM cells (106/mL) were
cultured for 7 days in RPMI medium 1640 with 2 mM of L-glutamine/1 mM
of sodium pyruvate/100 units/mL of penicillin/streptomycin/50 M of
2-mercapthoethanol/10% fetal calf serum supplemented with recombinant
macrophage colony-stimulating factor (M-CSF) for macrophage cultures
and granulocyte-macrophage colony-stimulating factor (GM-CSF) for
dendritic cell (DC) cultures (20 g/mL, PeproTech, Rocky Hill, NJ). Mice
were housed at Massachusetts General Hospital under specific pathogen-
free conditions. Animal experiments were carried out after approval and in
accordance with guidelines from the Subcommittee on Research Animal
Care of Massachusetts General Hospital.
Flow cytometry and immunohistochemistry
For flow cytometry, single-cell suspensions in phosphate-buffered saline
and 5% fetal calf serum and 0.1% sodium azide were labeled with
antimouse antibodies (Table 1). Antimouse antibodies used included:
Sca-1, c-kit, CD11b, CD11c, Gr-1, B220, CD43, IgM, IgD, CD25, CD44,
CD4, CD8, CD21, CD23, CD24, CD41 and CD61, CD93, IgD, TNP,
streptavidin conjugates (BD Biosciences, San Jose, CA), IgM, CD21,
CD23, CD45.1, CD45.2, Foxp3, Dx5 (eBioscience, San Diego, CA), peanut
agglutinin (PNA; Vector Laboratories, Burlingame, CA), and fluorescently
labeled antirat and antirabbit IgG secondary antibodies (Jackson Labora-
tory). Phycoerythrin-labeled CD1d tetramers were a kind gift from Svend
Rietdijk and Cox Terhorst (Harvard Medical School, Boston, MA). Foxp3
antibody-staining reagents were used according to the eBioscience proto-
col. Purified polyclonal rabbit anti-WASP antibody was generated as
described,17 and staining was performed with Fix and Perm permeabiliza-
tion kit (Invitrogen, Carlsbad, CA). Data were acquired on a FACSCalibur
cytometer (BD Biosciences) or on a BD LSR II Flow Cytometry and
analyzed using FlowJo for Mac version 8.2 (Tree Star, Ashland, OR). For
immunohistochemistry, 4-m cryostat spleen sections were fixed in ice-
cold acetone, labeled with antimouse antibodies for CD1d, B220, F4/80,
CD11b, CD11c, TNP (BD Biosciences), Sialoadhesin, SIGN-R1, MARCO,
and MOMA-1 (Serotec, Raleigh, NC) in phosphate-buffered saline with 5%
fetal calf serum and 0.3% Tween 20, and mounted in Mowiol (Calbiochem,
San Diego, CA). For Staphylococcus aureus uptake in the spleen, 25 g of
fluorescein isothiocyanate (FITC)-labeled organisms (Invitrogen) were
injected intravenously and spleens examined by immunohistochemistry
30 minutes after injection.
Slides were viewed with an Olympus Provis AX70 research system
microscope (Olympus Optical, Tokyo, Japan) using an UplanApo or UplanFl
lens at 10/0.40 Phl/0.17 and 20/0.50 Phl/0.17, respectively, and Mowiol
medium (Calbiochem, San Diego, CA). Images were acquired using a U-
PHOTO Universal Photo System camera (Olympus) model U-CMAD-2 and
were processed with MagnaFire 2.1c (Optronics, Goleta, CA) and Adobe
Photoshop CS version 8.0 (Adobe Systems, San Jose, CA).
BrdU incorporation, cell death, adhesion, and chemotaxis
For continuous in vivo bromodeoxyuridine (BrdU) labeling, mice were fed
BrdU (1 mg/mL from Sigma-Aldrich, St Louis, MO) in 10% sucrose-
supplemented drinking water for 6 days and thereafter with normal drinking
water for another 6 days. BrdU incorporation in spleen cells at days 3, 6, 9,
and 14 was determined using the FITC BrdU flow kit (BD Biosciences). For
cell death analysis, splenocytes stained with antibodies to CD21 and CD23
were labeled with FITC-conjugated annexin V and 7-amino-actinomycin D
(7-AAD; BD Biosciences). Dead cells were defined as 7-AAD cells and
apoptotic cells as 7-AAD annexin V. For adhesion to intercellular
adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule 1
(VCAM-1; R&D Systems, Minneapolis, MN), splenocytes were allowed to
adhere to ligand-coated microtiter plates for 2 hours.13 Adherent cells were
released by incubating for 15 minutes on ice in RPMI with 5 mM of
ethylenediaminetetraacetic acid. Adhesion was calculated as a percentage
of “input” samples that had been incubated in parallel on bovine serum
albumin-coated wells. For in vitro migratory response, splenocytes (2 105)
were allowed to migrate to S1P (Sigma-Aldrich) for 3 hours in Transwell
chemotaxis chambers (5 m; Corning Life Sciences, Acton, MA).
Cell sorting and real-time polymerase chain reaction
Splenic B cells were sorted on a FACSVantage (BD Biosciences).
Extraction of RNA was performed using Trizol (Invitrogen) and cDNA
generated using iScript cDNA Synthesis kit (Bio-Rad, Hercules, CA).
Real-time quantitative polymerase chain reaction (PCR) was performed in
Table 1. Markers used to define HPC and lineage cells
Hematopoietic lineage cells Marker
T-cell lineage
THY
DN1 CD25 CD44 Lin
DN2 CD25 CD44 Lin
DN3 CD25 CD44 Lin
DN4 CD25 CD44 Lin
DP CD4 CD8
THY/SPL
CD4 SP CD4 TCRhi
CD8 SP CD8 TCRhi
nTreg Foxp3 CD4 CD25
NKT TCR CD1d
B-cell lineage
BM
HPC Sca1 ckit Lin*
Fr A CD43 B220lo CD24
Fr BC CD43 B220lo CD24
Fr D CD43 B220 IgM IgD CD93
Fr E CD43 B220 IgM IgD CD93
Fr F CD43 B220 IgM IgD CD93
SPL
T1 CD23 IgM CD24 CD21/lo
T2-FO CD23 CD24 CD21lo
FO CD23 IgMint CD24lo CD21
T2-MZP CD23 IgMhi CD24 CD21hi
MZ CD23 IgM CD24 CD21hi
PT
B1a CD19hi CD5 B220lo
B2 CD19lo CD5 B220hi
PPs
PNA B220 CD19 PNA
PNA B220 CD19 PNA
Myeloid cells
BM/SPL
Imm N Gr1lo CD11b
Mat N Gr1hi CD11b
SPL/culture
NK Dx5 TCR
DC CD11b CD11c
Mo/Ma CD11b CD11c
PB
Platelets CD41 CD61
B indicates B cell; B1/B2, peritoneal B cells; BM, bone marrow; culture, bone
marrow cells cultured for 7 days with M-CSF or GM-CSF; DC, dendritic cell; DN,
CD4CD8 double-negative; DP, CD4CD8 double-positive; FO, follicular; Fr, fraction;
HPC, hematopoietic progenitor cells; Mo/Ma, monocyte/macrophage; MZ, marginal
zone; N, neutrophil; NK, natural killer cell; NKT, NK T cell; nTregs, naturally occurring
T cells; PB, peripheral blood; PNA, peanut agglutinin; PPs, Peyer’s patches; PT,
peritoneum; SP, CD4 or CD8 single-positive; SPL, spleen; T1, transitional 1 B cell; T2
transitional 2 B cell; T2-FO, transitional 2 follicular precursor B cell; T2-MZP,
transitional 2 marginal zone precursor B cell; and THY, thymus.
*Lin: CD11b, CD11c, Gr-1, CD4, CD8, B220.
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the DNA Engine Opticon 2 system (MJ Research, Watertown, MA) using
the iQTMSYBR Green super mix (Bio-Rad). The thermal cycling condi-
tions were 4 minutes at 95°C, followed by 50 cycles at 94°C for 15 seconds,
62°C for 15 seconds, and 72°C for 45 seconds. The primer sequences were
S1P1 5-GTGTAGACCCAGAGTCCTGCG-3 (forward) and 3- AGCTTT-
TCCTTGGCTGGAGAG-5 (reverse), S1P3 5-GGAGCCCCTAGACGG-
GAGT-3 (forward) and 3-CCGACTGCGGGAAGAGTGT-5 (reverse),
and hypoxanthine phosphoribosyltransferase (HPRT) 5-AGGTTG-
CAAGCTTGCTGGT-3 (forward) and 3-TGAAGTACTCATTATAGT-
CAAGGGCA-5 (reverse). The test sample CT was calculated by subtract-
ing the calibrator gene HPRT CT value from the test sample CT value and
thus represented the relative quantity of the target mRNA normalized to
HPRT mRNA. The mRNA content of test sample in WT follicular B cells
was defined as 1 arbitrary unit.
TNP-Ficoll immunization
For TI-2 antigen responses, age- and sex-matched C57BL/6 mice were
injected intravenously with 2,4,6-trinitrophenol (TNP)-Ficoll (Biosearch
Technologies, Novato CA). Uptake of TNP-Ficoll in the MZ and by MZ B
cells was examined 30 minutes and 3 hours after injection, and anti-TNP
IgM and IgG3 antibody titers were measured by enzyme-linked immunosor-
bent assay at day 7. The samples were run in triplicates and corrected for
background binding.
Statistics
Data are expressed as mean plus or minus SD where indicated. Statistical
significance between groups was assessed by 2-tailed Student t test and analysis
of variance. Differences were considered significant when P was less than .05.
Results
Selective advantage for WASP-expressing cells in WASP/
mice
Prior studies have suggested that WASPexpression confers developmen-
tal, proliferative, and/or functional advantage to various hematopoietic
populations.1,18–20 Using the natural competitive setting of WASP/
mice on Balb/c background, we sought to determine the proportion of
cells expressing WASP in different hematopoietic cell lineages (Table
1). Preliminary analysis of WASP/ mice revealed that it was difficult
to appreciate the contribution of WASP cells in those mice that had a
high proportion of WASP hematopoietic progenitor cells (HPCs).
Accordingly, we included in our study those WASP/ mice that
expressed less than 65% WASP HPCs (43% 13%, n 13 mice).
In the thymus, no advantage for WASP-expressing cells was
observed during development of double-negative (DN) and double-
positive cells (DP) compared with the proportion of WASP-expressing
cells in BM HPCs (HPCs: 43% 13%; DN: 52% 17%; DP:
62% 16%, P not significant, Figure 1A). The percentage of
WASP cells was significantly higher among single-positive (SP) CD4
and CD8 cells (CD4SP: 65% 15%; CD8SP: 64% 16%, P	 .01,
Figure 1A). Remarkably, the majority of nTregs and NKT cells in the
thymus expressed WASP (84% 12% and 83% 11%, respectively,
P	 .005, Figure 1A). An even greater selective advantage for WASP-
expressing SP CD4 and CD8 T cells, nTregs and NKT cells was
observed in the spleen (CD4: 72% 9%; CD8: 74% 9%; nTregs:
93% 4%; NKT: 86% 8%, respectively, P	 .005, Figure 1A). In
keeping with a strong advantage for WASP-expressing nTregs (as we
previously have published)21 and NKT cells in WASP/ mice, the
absolute number of these cells was reduced in WASP/mice compared
with control mice (NKT cells in thymus: WT 149 20 103 and
WASP/ 111 31 103, n 4, P	 .005; and spleen WT
131 3 103 and WASP/ 89 8 103, n 4, P	 .005).
In the BM, we used the Hardy classification22 for central B-cell
development and included CD93 to distinguish immature and
mature B cells (Figures 1B left panel and S1A, available on the
Blood website; see the Supplemental Materials link at the top of the
online article). There was no advantage for WASP-expressing cells
during the pro-B cell to immature B cell stages (Hardy fraction [Fr]
A: 33%  8% WASP-positive; Fr B  C: 34%  9%; Fr D:
33%  5%; Fr E: 42%  5%; P  not significant, Figure 1B left
panel). In contrast, WASP-expressing recirculating IgD B cells
(Fr F) showed selective advantage over WASP cells compared
with pro-B cells (Fr A: 33%  8%; Fr F: 60%  12%, P 	 .005,
Figure 1B left panel). In the spleen, compared with pro-B cells (Fr
Figure 1. Selective advantage of WASP-expressing cells in WASP/ mice.
HPCs and hematopoietic lineage cells were defined by surface and intracellular
markers, labeled with anti-WASP antibodies, and analyzed by flow cytometry.
Percentage of WASP-expressing cells is indicated in (A) the T-cell lineage, (B) the
B-cell lineage, and (C) the myeloid lineage. Each color represents data from one
mouse. Black bar represents the mean of the group. B indicates B cell; B1/B2,
peritoneal B cells; BM, bone marrow; DC, dendritic cell; DN, CD4CD8 double-
negative; DP, CD4CD8 double-positive; FO, follicular; Fr, fraction, HPC, hematopoi-
etic progenitor cells; Mo/Ma, monocyte/macrophage; MZ, marginal zone; N, neutro-
phil; NK, natural killer cell; NKT, NK T cell; nTregs, naturally occurring T cells; PB,
peripheral blood; PNA, peanut agglutinin; PPs, Peyer patches; PT, peritoneum; SP,
CD4 or CD8 single-positive; SPL, spleen; T1/T2, transitional 1/2 B cell; T2-FO,
transitional 2 follicular precursor B cell; T2-MZP, transitional 2 marginal zone
precursor B cell; THY, thymus. In vitro cultured Mo/Ma and DCs were obtained by
culturing BM cells in vitro for 7 days with M-CSF and GM-CSF, respectively. P values
use a t test to compare percentage of WASP-expressing cells in the T-cell, B-cell
(right panel), and myeloid lineages to that of HPCs and for the B-cell lineage (left
panel) to that of Fr A (pro-B) cells: *P 	 .05, **P 	 .01, ***P 	 .005.
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A), WASP-expressing T1 B cells showed no selective advantage
over WASP cells (T1: 39%  9%, P  not significant, Figures
1B left panel, S1). In contrast, all other B-cell populations showed
advantage for WASP-expressing cells (T2-FO: 57%  8%; FO:
72%  9%; T2-MZP: 87%  5%; MZ: 92%  4%, P 	 .005,
Figures 1B left panel, S1). This advantage was particularly striking
among MZ B cells where at least 88% of cells expressed WASP. A
higher proportion of WASP-expressing cells was also found among
B1 and B2 peritoneal B cells (B1: 77%  9%, P 	 .01; B2 cells:
74%  20%, P 	 .05, Figure 1B right panel). To define a possible
advantage for WASP-expressing cells in the germinal center (GC)
reaction, we analyzed expression of WASP and of PNA, a marker
of GC B cells, in Peyer patches, and found that the proportion of
WASP B cells was consistently higher among PNA than among
PNA cells (84%  11% vs 68%  19%, P 	 .01, Figure 1B right
panel). To address the GC response on antigen challenge, WASP/
mice were immunized with sheep red blood cells. The proportion of
WASP-expressing cells at day 6 after immunization was signifi-
cantly higher among PNA compared with PNA cells (82% 6%
vs 60%  8%, P 	 .005, Figure S2), suggesting that expression of
WASP may be required for optimal GC responses.
Consistent with recent findings,18 WASP expression did not
impart a selective advantage in the myeloid compartment. In
particular, the percentage of WASP-expressing cells among BM
immature and mature neutrophils, splenic DCs, macrophages,
neutrophils, and NK cells were similar to that found among BM
HPCs (Figure 1C). Importantly, however, a higher proportion of
circulating platelets were found to be WASP compared with BM
HPCs (60%  17% vs 43%  13%, P 	 .05). Because a previous
study suggested an advantage for WASP-expressing myeloid cells
using in vitro colony forming assays,20 we also analyzed the
proportion of WASP-expressing BM WASP/ cells cultured in
vitro for 7 days with M-CSF to generate macrophages or with
GM-CSF to generate myeloid DCs and found no evidence for
outgrowth of WASP-expressing cells (Figure 1C).
Abnormalities of MZ B cells and MZMs in WASP/ mice
WAS patients and WASP/ mice have a reduced number of MZ
B cells.8,9 We have previously shown that MZ B-cell positioning is
dependent on MZMs.15 To test the possibility that the reduced
number of MZ B cells in WASP/ mice could be caused by
abnormalities in MZMs or other MZ resident cells (schematically
depicted in Figure 2A), we examined spleen sections from WT and
WASP/ Balb/c mice by immunohistochemistry. We confirmed
that the number of MZ B cells defined by CD1d and B220
expression was markedly decreased in WASP/ mice (Figure 2B
arrowheads). Positioning of metallophilic (MOMA-1sialoadhe-
sin; Figure 2B), red pulp (F4/80), and CD11b macrophages, as
well as CD11cCD11b DCs (Figure 2C), was similar in WT and
WASP/ mice. In contrast, MZMs, defined by MARCO and
SIGN-R1 receptor expression, were virtually absent in WASP/
Balb/c mice (Figure 2D arrows) and reduced as well in WASP/
C57BL/6 mice (Figure S3).
To investigate the functional consequences of these abnormali-
ties in vivo, we injected WT and WASP/ mice intravenously with
FITC-labeled S aureus and examined bacterial uptake in the spleen.
As previously described,15 S aureus were captured by MZMs, but
not by MOMA metallophilic macrophages in WT mice (Figure
2E). However, uptake of S aureus was impaired in WASP/ mice,
and aberrant colocalization of S aureus with metallophilic macro-
phages was observed (Figure 2E).
WASP-deficient MZ B cells are reduced independently of the
presence of MZMs
Because MZMs are important for MZ B-cell retention,15 we sought
to determine whether the loss of MZ B cells is caused by the lack of
MZMs in WASP/ mice. We established mixed BM chimeras of
WT (expressing CD45.1) and WASP/ (CD45.2) BM cells.
Lethally irradiated WASP/ mice were injected with WT or
WASP/ BM cells in a 1:3 ratio and analyzed 9 to 13 weeks after
transplantation (schematized in Figure 3A). As a control, recipient
mice received cells from WT or from WASP/ mice only (Figure
3B left and center panels). In the BM of chimeric mice, we found
that the proportion of WASP and WASP cells among pro/pre-B
cells was in a 1:3 ratio (23%  5% WASP cells, n  7 mice),
supporting our data that WASP-deficient progenitor cells are not
impaired in their ability to migrate to, and repopulate, the BM.
Reconstitution of the MZ, and the proportion of MZ B cells, was
similar in the chimeric mice and in mice that received BM cells
from WT mice (Figure 3B,C). In contrast, mice that received
WASP-deficient BM cells alone had a markedly reduced proportion
of MZ B cells and MZMs (Figure 3B,C). We next evaluated the
origin of splenic B cells in the chimeric animals and found that only
10% of the MZ B cells were of WASP-deficient origin (Figure 3C).
This contrasts with the higher proportion of WASP cells in T1,
FO, and T2-MZP cells (Figures 3C, 4A). Taken together, these
Figure 2. MZ B cells and MZMs are reduced, and S aureus uptake aberrant in
WASP-deficient mice. Immunohistochemistry of spleen sections from WT and
WASP/ mice. (A) Schematic representation of a B-cell follicle and the MZ in the
spleen. Black arrows indicate the MZ. (B) Reduced number of MZ B cells (CD1d
B220) and normal localization of metallophilic macrophages (MOMA-1 Sialoadhe-
sin) in WASP/ spleens relative to WT spleens. Black arrowhead represents the
MZ. (C) Normal localization of red pulp macrophages (F4/80), CD11b macro-
phages, and DCs (CD11c). (D) Reduced number of MZMs (MARCO SIGN-R1) in
WASP/ spleens compared with WT spleens. Black arrow represents MZMs in the
MZ. (E) Localization of S aureus 30 minutes after intravenous injection. Note that S
aureus almost exclusively colocalize with MARCO MZ macrophages in WT mice,
whereas WASP/ mice show aberrant localization of S aureus. White arrowhead
represents the MZ. FO indicates B-cell follicle; MZ, marginal zone; RP, red pulp.
Original magnifications: panels B to D,10; D,20.
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results support the notion that WASP plays a cell-intrinsic role for
the presence of MZ B cells independently of MZMs.
Peripheral B-cell development and homeostasis in
WASP/ mice
Our data in WASP/ mice and in the BM chimeras revealed a
strong selection of WASP-expressing cells among T2-MZP B-cell
precursors and MZ B cells (Figures 1B and 4A, respectively). In
addition, we found a normal number of T1, and T2-FO in WASP/
mice, whereas both the proportion and the absolute number of FO
B cells, and especially of T2-MZP and MZ B cells, were reduced in
WASP/ mice compared with WT mice (Figure 4B,C). Together,
these results imply that WASP is required for development and/or
peripheral homeostasis of B cells. It has been shown that high BCR
signaling favors the development of FO B cells, whereas low BCR
signaling strength promotes MZ B-cell development.12 To evaluate
whether lowering the strength of BCR signaling might restore the
MZ B-cell compartment in WASP/ mice, we bred mice carrying
the btkxid mutation that have reduced BCR signaling with WASP-
deficient mice.23,24 We confirmed prior studies24 that demonstrated
that btkxid mice have a normal percentage of MZ B cells (Figure
S4). We found that the proportion of MZ B cells is partially restored
in WASP//btkxid double-mutant mice (Figure S4). To examine the
turnover rate of peripheral B cells in vivo, we performed a BrdU
pulse-chase experiment. Mice were fed BrdU in the drinking water
for 6 days and followed thereafter for another 6 days (Figure 4D). If
WASP deficiency mainly affects development of MZ B cells, we
would expect to see less BrdU cells at this stage, reflecting
decreased transition from newly formed B cells. If WASP influ-
ences the turnover rate of B cells, we would expect an increased
proportion of BrdU cells. At day 3, we found an increased
proportion (Figure 4D) of BrdU cells in the T2-FO, FO, T2-MZP,
and MZ B-cell subsets in WASP/ mice compared with WT mice,
suggesting that WASP is required for normal turnover rates of
B cells. Notably, the absolute number of BrdU MZ B cells was
similar in WT and WASP/ mice (data not shown), implying that
generation of MZ B cells is unaffected in WASP/ mice. At day 9,
there is a tendency to increased proportion of T2-MZP and MZ
B cells in WASP/ mice compared with WT mice, and this
difference becomes significant at day 14. Together, these data
indicate that WASP is required for maintenance of peripheral
homeostasis of MZ B cells.
WASP-deficient MZ B cells show impaired in vitro migration
to S1P
To evaluate whether the reduced number of MZ B cells in WASP/
mice resulted from decreased survival, we examined cell death in
freshly isolated splenocytes. The frequency of necrotic (7-AAD)
and apoptotic (7-AADannexin V) cells among FO and MZ
B cells was similar in WT and WASP/ mice (Figure 5A). We next
examined whether WASP-deficient MZ B cells were impaired in
adhesion to ICAM-1 and VCAM-1 and in their migratory response
to S1P, all of which are essential for correct MZ positioning.13,14 As
previously described,13 MZ B cells from WT mice exhibited
increased adhesive response to ICAM-1 and VCAM-1 compared
with FO B cells (Figure 5B). We found that the adhesive response
Figure 3. WASP-deficient MZ B cells are reduced in number
independent of MZMs. (A) Schematic representation of genera-
tion of BM chimeric mice. WT (expressing CD45.1) and WASP/
(CD45.2) BM cells at a 1:3 ratio were injected into lethally irradiated
WASP/ recipient mice. Mice were analyzed 9 to 13 weeks after
transplantation. Control mice received WT or WASP/ BM alone.
(B) Immunohistochemistry of spleen sections from mice receiving
WT BM (left panel), WASP/ BM (middle), and mixed WT:
WASP/ BM (right). Note that the MZ architecture in WT:WASP/
BM chimeric mice is fully restored. (C) Splenocytes were labeled
with anti-CD21, CD23, and IgM and analyzed by flow cytometry.
(Top panel) The percentage of FO and MZ B cells in reconstituted
mice is shown for the various conditions as illustrated in panel B.
Note that WT:WASP/ BM chimeric mice have fully restored MZ
B-cell population (right). (Bottom panel) The percentage of WASP/
CD45.2-expressing FO and MZ B cells is shown. Note the low
proportion of WASP/ MZ B cells in the WT:WASP/ BM
chimeric mice (right). The data are representative of 2 independent
experiments, in which n  7 mice were analyzed (original magnifi-
cation10).
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of WASP/ T1, FO, T2-MZP, and MZ B cells was similar to that of
WT cells (Figure 5B). Finally, we used an in vitro chemotaxis assay
to examine the chemotactic response of WASP/ B cells to S1P.
MZ B cells from WT mice showed a dose-dependent migratory
response to S1P, as previously described (Figure 5C).14 In contrast,
MZ B cells from WASP/ mice failed to respond to S1P (Figure
5C). Next, we used quantitative real-time PCR to analyze expres-
sion of the S1P receptors, S1P1 and S1P3. T2-MZP and MZ B cells
from WT mice showed a moderate increase in S1P1 expression
compared with FO B cells, whereas S1P3 expression was increased
5- to 20-fold (Figure 5D), as previously described.14 WASP/ mice
showed reduced expression of S1P1 in T2-MZP B cells, and of S1P3
in MZ B cells (Figure 5D).
WASP-deficient mice show reduced specific immune response
to TNP-Ficoll
It was recently shown that positioning of MZ B cells in the MZ is
required for capture of blood-borne antigens, such as TNP-Ficoll.25
On antigen uptake, MZ B cells shuttle between the MZ and follicle
to deliver antigen to follicular DCs, and this shuttling is dependent
on CXCL13 and S1P responsiveness.25 We reasoned that the
reduced number of MZ B cells in WASP-deficient mice together
with abolished S1P responsiveness would reduce the immune
response to the type 2 T-independent antigen TNP-Ficoll, espe-
cially under limiting concentrations of antigen. WT and WASP/
mice were injected intravenously with 2.5 g of TNP-Ficoll when
12 to 14 weeks old. We first examined antigen uptake in the MZ.
Consistent with a prior study,25 30 minutes after injection, TNP-
Ficoll was detected in the MZ of WT spleens; and after 3 hours, the
TNP-Ficoll localized exclusively in B-cell follicles (Figure 6A left
panels). In WASP/ mice, less TNP-Ficoll was found in the MZ
after 30 minutes; and after 3 hours, TNP-Ficoll was detected in
WASP/ follicles but to a lesser extent compared with WT
follicles. Likewise, we found that WASP/ MZ B cells had
reduced uptake of TNP-Ficoll compared with WT MZ B cells
(Figure 6A right panel). We next sought to determine the specific
antigen response, and serum titers of anti-TNP IgM and IgG3 were
measured 7 days after immunization. When immunized with a low
dose (2.5 g) of TNP-Ficoll, WASP-deficient mice showed de-
creased IgM and IgG3 response (Figure 6A). A high dose of
TNP-Ficoll (25 g) elicited higher IgM and IgG3 responses in both
WT and WASP/ mice (Figure S5A). Although serum IgM and
IgG3 levels did not differ between unimmunized WT and WASP/
mice,16 the latter had significantly higher levels of “natural” IgM
anti-TNP antibodies (Figure S5B). Likewise, the level of “natural”
IgM antiphosphorylcholine antibodies was significantly higher in
WASP/ than in age-matched WT mice (Figure S5C).
Discussion
Defining the requirement of WASP expression for the selective
advantage of specific cell lineages is important for the development
of gene therapy and transplantation-based treatment strategies.
Using the natural competitive setting of WASP/ mice, we have
shown that WASP is not required for BM HPC maintenance and
myeloid cell differentiation, whereas it is important for the
development and maturation of T-cell and B-cell lineage cells.
Consistent with recent data from our group,21 we found no selective
advantage for WASP cells in thymopoiesis during progression to
DP cells. WASP conferred some advantage in CD4 and CD8 SP
T cells that was most pronounced in the periphery. Carrier females
of WAS show selective inactivation of the mutated X chromosome
already in CD34 cells,26 thus preventing analysis of the role of
WASP along hematopoietic development in this setting. Our data in
WASP/ mice are consistent with the demonstration that genetic
reversion confers advantage mostly to mature T cells in patients
with WAS27,28 and with data showing selective accumulation of
WASP T cells after introduction of the WASP gene into HPCs of
WASP/ mice.19,29 The relative role of WASP in T-cell develop-
ment may vary between human and mice because of species-
specific differences in the level of N-WASP expression. In particu-
lar, mice devoid of both N-WASP and WASP in T cells had a severe
block in thymocyte development.21
The most pronounced selective advantage for WASP-expressing
T cells was found within Tregs and NKT cells. Several recent
Figure 4. Peripheral B-cell development and homeostasis in WASP/ mice.
(A) Left panel; flow cytometric analysis of WT:WASP/ BM chimeric mice to define
the percentage of WASP (CD45.2) cells in the T1, FO, T2-MZP, and MZ B-cell
populations, using CD21, CD23, and IgM as markers. The middle panel shows the
results of one representative experiment, indicating (from top to bottom) the
proportion of WASP (CD45.2) cells in T2-MZP, FO, MZ B cells, and T1 cells,
respectively. The right panel shows the percentage of WASP-expressing (CD45.1)
cells in the indicated B-cell populations. The hatched line indicates the 25% of
WASP BM cells that were used for transplantation. The right panel represents data
from one of 2 similar experiments with n  7 mice. (B) Proportion of T1, T2-FO, FO,
T2-MZP, and MZ B cells in WT and WASP/ mice (n  10 mice per group).
(C) Absolute numbers of T1, T2-FO, FO, T2-MZP, and MZ B cells in WT and
WASP/ mice (n  10 mice per group). (D) In vivo BrdU labeling. (Top panel) Mice
were fed BrdU in the drinking water for 6 days (pulse) and followed for another 6 days
(chase). Proportion of BrdU positive cells was assessed at day 3, 6, 9, and 14.
(Bottom panels) The proportion of BrdU cells of T1, T2-FO, FO, T2-MZP, and MZ
B cells as defined by CD21, CD23, CD24, and IgM expression is shown (n  4 mice
per group). *P 	 .05, **P 	 .01, ***P 	 .005.
4144 WESTERBERG et al BLOOD, 15 NOVEMBER 2008  VOLUME 112, NUMBER 10
 For personal use only. at Harvard Libraries on August 26, 2013. bloodjournal.hematologylibrary.orgFrom 
studies have demonstrated a critical role for WASP in Treg
function.18,30-32 We have previously demonstrated a reduced num-
ber of Tregs in the thymus of WASP-deficient animals.31 We now
show that expression of WASP confers a strong selective advantage
to Tregs both in the thymus and in the spleen of WASP/ mice.
These data differ in part from a previous observation by Humblet-
Baron et al that demonstrated selective advantage for WASP-
expressing Tregs in the periphery, but not in the thymus of
WASP/ mice18 and may reflect use of different murine strains. We
found strong selective advantage for WASP-expressing NKT cells
both in the thymus and in the periphery; in addition, WASP/ mice
had a reduced number of NKT cells both in the thymus and in the
periphery. Natural Tregs and NKT cells are detected in WASP-
deficient mice indicating that lack of WASP does not prevent
development of these cell types. However, WASP may play a role
in the maintenance and/or fitness of these cell lineages as we
observed a striking advantage for WASP-expressing nTregs and
NKT cells in WASP/ mice. Because NKT cells have important
immunomodulatory activity,33 numerical or functional defects of
such cells might contribute to the immunopathology of WAS
patients and WASP/ mice.
Because WASP-deficient myeloid cells have been demonstrated
to have several functional defects both in vitro and in vivo,34-39
restoration of WASP expression in the myeloid compartment may
be required for successful treatment of WAS patients. Two recent
studies show that WASP gene transfer into HPC from WAS patients
reconstitutes the actin cytoskeleton in myeloid progeny cells
differentiated in vitro.5,40 Moreover, a modest advantage of WASP-
expressing neutrophils and myeloid cells was seen using BM
competitive repopulation experiments.29 However, we found little
or no evidence of selective advantage for WASP expressing
myeloid cells in WASP/ mice and on in vitro culture with M-CSF
or GM-CSF. Overall, the selection for WASP-expressing myeloid
cells appears less robust than in other lineages. This may have
significant implications for the development of gene therapy
protocols for WAS, although in humans expression of WASP
appears to confer a significant advantage already in HPCs, as
shown in carrier females.26
Thrombocytopenia is a major complication in WAS and fre-
quently the cause for fatal outcome of the disease.41,42 Lack of
donor myeloid engraftment is associated with increased risk of
persistent thrombocytopenia after HSCT.3,43 Our data in WASP/
mice have shown that, despite lack of selective advantage in the
Figure 5. WASP-deficient MZ B cells show impaired in vitro migration to S1P. (A) Flow cytometric analysis of cell death in freshly isolated FO and MZ B cells, identified
based on CD21 and CD23 expression. Necrotic cells were defined as 7-AAD (left panel) and apoptotic cells as 7-AAD annexin V (right). N  6 mice per group. (B) Adhesive
response of T1, FO, T2-MZP, and MZ B cells to ICAM-1 (left panel) and VCAM-1 (right). Splenocytes were allowed to adhere to tissue culture plates coated with indicated
ligands for 2 hours. Adherent cells were released by ethylenediaminetetraacetic acid, stained for CD21, CD23, and IgM to define B-cell subsets, and enumerated by flow
cytometry. The percentage of adhesive cells as a fraction of total input cells is shown as mean values ( SD). This experiment is representative of 2 similar ones with n  3
mice per group. (C) Migratory response of MZ B cells to S1P was determined by an in vitro chemotaxis assay. The percentage of cells that migrated after 3 hours in the
chemotaxis assay was determined and represents the mean value ( SD) of n  3 mice per group. This experiment represents 2 similar experiments. (D) Real-time PCR
analysis of S1P1, and S1P3 in FO, T2-MZP, and MZ B cells. B cells from 3 mice per group were pooled and cell-sorted based on CD21, CD23, and IgM expression. Samples
were run in triplicate, and the target mRNA was normalized to HPRT mRNA. The mRNA content of test sample in WT FO B cells was defined as 1 arbitrary unit. Mean value
( SD) of triplicates is shown, and the data are representative of 3 similar experiments. *P 	 .05, **P 	 .01.
Figure 6. WASP-deficient mice show reduced specific immune response to
TNP-Ficoll. WT and WASP/ mice when 12 to 14 weeks old were injected
intravenously with 2.5 g of TNP-Ficoll. (A) Uptake of TNP-Ficoll in spleens
30 minutes and 3 hours after injection. (Left panel) Spleen sections were labeled to
detect TNP-Ficoll and MOMA metallophilic macrophages to define the MZ. Note the
reduced TNP staining in the MZ at 30 minutes (top panels) and in the follicles at
3 hours (bottom panels) in WASP/ mice compared with WT mice (original
magnification 20). (Right panels) MZ B cells were labeled with anti-TNP and
analyzed by flow cytometry (n  5). (B) Anti-TNP IgM and IgG3 antibody titers were
determined at day 7 after immunization by enzyme-linked immunosorbent assay.
Each group represents mean values ( SD) from n  5 mice, which were corrected
for background binding. FO indicates B-cell follicle; MZ, marginal zone; non-B,
lymphocytes negative for CD21 and IgM; RP, red pulp. *P 	 .05, **P 	 .01.
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myeloid compartment, a moderate excess of WASP platelets was
present in the circulation. Although it remains to be seen whether such
increase reflects advantage in the number and/or differentiation of
WASP-expressing megakaryocytes or an increased peripheral consump-
tion of WASP-negative platelets, these data represent an encouraging
result in view of the potential use of gene therapy in WAS.
The role of WASP in B-cell development, maturation, and
function is controversial. Patients with WAS have a reduced
number of circulating B lymphocytes.44 On the other hand, analysis
of WAS patients in which somatic reversion occurred in a common
lymphoid progenitor failed to demonstrate significant advantage
for WASP-expressing B cells, suggesting that expression of WASP
does not play a critical role in B-cell differentiation.45 Although our
data confirm that WASP does not play an important role in early
stages of B-cell development in the BM, we found that BM mature
recirculating B cells as well as follicular and MZ B cells in the
spleen of WASP/ mice were comprised mostly of WASP cells,
suggesting that WASP is involved in peripheral B-cell maturation
and/or homeostasis. Consistent with our previous findings that
WASP may be required for optimal GC reaction,8 we show that the
proportion of WASP cells was higher among PNA than among
PNA B cells from the Peyer patches of unimmunized WASP/
mice and from the spleen of immunized mice.
We previously reported that WASP deficiency in humans and
mice is associated with severe abnormalities of the MZ and a
marked reduction of MZ B cells.8,9 We now provide several
independent lines of evidence that WASP is critically involved in
MZ B-cell biology. MZ B cells from WASP/ mice are almost
entirely composed of WASP cells. This selective advantage for
WASP-expressing cells is already apparent in T2-MZP cells.
Moreover, we have found that the proportion of T2-MZP and of
MZ B cells is significantly reduced in WASP/ mice. Differentia-
tion of MZ B cells has been shown to be dependent on BCR-
mediated signaling, such that MZ B cells require less signaling
through the BCR for development.12 We found that lowering BCR
signaling in WASP/y/BTKxid/y mice partially rescued differentia-
tion of MZ B cells compared with WASP/ mice, indicating that
aberrant BCR-mediated signaling may contribute, at least in part,
to the reduced number of MZ B cells in WASP/ mice. Further-
more, we found increased proliferation in MZ B cells from
WASP/ mice (as shown by analysis of BrdU incorporation) and
similar absolute number of newly generated MZ B cells in
WASP/ and WT mice. In the absence of clear abnormalities in
apoptosis, these data suggest that the reduced number of MZ
B cells in WASP-deficient mice might result from abnormalities of
homeostasis and/or retention.
S1P is critically involved in positioning of MZ B cells.25 We
have shown that WASP-deficient MZ B cells have reduced
migration in response to S1P. We had previously shown that
WASP-deficient B lymphocytes are impaired in response to
CXCL13.8 MZ B cells shuttle between the MZ- and B-cell follicles
in response to S1P and CXCL13, respectively.25 This shuttling is
important in delivering blood-borne antigens captured in the MZ to
follicular DCs. In this regard, it is possible that the reduced
responsiveness of WASP-deficient MZ B cells to S1P and to
CXCL13 contributes to the impaired antibody response to T-
independent antigens.
Organization of the MZ is dependent both on MZ B cells and on
a MZM. Transient depletion of MZMs with clodronate liposome
has been shown to result in a severe reduction of MZ B cells.15 On
the other hand, progressive disappearance of MZ B cells is
associated with simultaneous decline in the number of MZMs,
resulting in disruption of the MZ architecture.46 To define whether
loss of MZ B cells and MZMs in WASP/ mice are related events,
we performed BM chimeric repopulation experiments using cells
from WASP/ and WASP/ mice. Our data have shown that, even
when the MZM compartment is restored, differentiation of MZ
B cells is strictly dependent on WASP, indicating a B-cell intrinsic
role of WASP expression in MZ B-cell development.
The severe deficiency of MARCO MZMs in WASP-deficient
mice might play an important role in the susceptibility of WAS
patients to invasive infections by encapsulated pathogens.41 We
have found that the severe reduction of MZMs in WASP/ mice
results in aberrant uptake of S aureus. Moreover, MARCO and the
scavenger receptor SR-A have the capacity to bind apoptotic cells,
a major source of autoantigens.47 Mice double-deficient in the
expression of MARCO and SR-A develop anti-DNA antibodies at
high titers, both spontaneously and after injection with apoptotic
cells, indicating that clearance of apoptotic cells is needed for
correct regulation of B-cell tolerance. Peritoneal macrophages
from WASP-deficient mice show decreased uptake of apoptotic
cells48 and WASP-deficient mice produce anti-dsDNA antibodies.18
We have now shown that WASP/ mice have increased levels of
anti-TNP and antiphosphorylcholine “natural” IgM, which have
been associated with low-affinity and potentially autoreactive IgM
responses.49
In conclusion, our data show that WASP controls lymphoid
maturation and homeostasis and plays a critical role for WASP in
MZ development and organization. These observations provide
novel insight into the immunodeficiency of WAS and may guide
therapeutic approaches dependent on gene transfer.
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